Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergy Clear all
Completed No phase listed Observational

Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study

NCT06128707
View directory record Official record
Conditions
Motion Sickness
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
20 Years to 40 Years
Enrollment
59 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D Replacement on Insulin Sensitivity

NCT01268111
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Ergocalciferols, Placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

NCT01860534
View directory record Official record
Conditions
Light Sensitivity
Interventions
eye covers
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

NCT00723021
View directory record Official record
Conditions
Asthma
Interventions
PF-04191834, zileuton, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • North Dartmouth, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 23, 2026, 11:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eating With Eosinophilic Esophagitis (EoE)

NCT03581838
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Observed eating session
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jul 23, 2026, 11:23 PM EDT
Terminated Early Phase 1 Interventional

A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

NCT03427021
View directory record Official record
Conditions
GI Patients on Oxaliplatin Containing Regimen
Interventions
Oxaliplatin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jul 23, 2026, 11:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Influence of Baseline Sensitivity and Expectation on Exercise-induced Hypoalgesia in Young Healthy Adults

NCT03871504
View directory record Official record
Conditions
Healthy Subjects
Interventions
Submaximal isometric exercise
Other
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

NCT03620747
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab SAR231893 (REGN668)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jul 23, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

NCT06998238
View directory record Official record
Conditions
Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions
Mediterranean-based, carbohydrate restricted, calorie reduced diet
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

NCT03215758
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

NCT01710449
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Diseases
Interventions
perfluorinated gas/oxygen mixture
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 23, 2026, 11:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skin Microbial Ecology in Atopic Dermatitis

NCT04170244
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Healthy
Interventions
AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
Other
Lead sponsor
University of Rochester
Other
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2010 · Synced Jul 23, 2026, 11:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Recruiting Not applicable Interventional

Meeting the Needs of Young Hispanic Autistic Children

NCT06733584
View directory record Official record
Conditions
Autism
Interventions
Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze, Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Months to 42 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Lawrence, Kansas • Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed No phase listed Observational

Exercise in Insulin-Resistant Minority Adolescents

NCT00345436
View directory record Official record
Conditions
Insulin-Resistance
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 11:23 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults

NCT02086565
View directory record Official record
Conditions
Asthma, Communication
Interventions
Portal training and home visits, Portal training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Jul 23, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT07220577
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GIA632, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Fremont, California • Rockville, Maryland • Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Change in Permeability of the Small Intestine After Treatment With Gluten

NCT02098057
View directory record Official record
Conditions
Gastrointestinal Disorders
Interventions
Gluten Healthy, Placebo
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jul 23, 2026, 11:23 PM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 23, 2026, 11:23 PM EDT